Following the successful and proven concept used in 'Bioactive Heterocyclic Compound Classes' by the same editors, this book is the first to present approved pharmaceutical and agrochemical compounds classified by their carboxylic acid functionality in one handy volume.
Each of the around 40 chapters describes one or two typical syntheses of a specific compound class and provides concise information on the history of development, mode of action, biological activity and field of application, as well as structure-activity relationships. In addition, similarities and differences between pharmaceuticals and agrochemicals are discussed in the introduction.
Written by a team of experts in the field, this is a useful reference for researchers in academia and chemical or pharmaceutical companies working in the field of total synthesis and natural product chemistry, drug development, and crop protection research.

Clemens Lamberth is a senior team leader in the crop protection research department of Syngenta AG, Switzerland. He studied chemistry at the Technical University of Darmstadt, Germany, where he obtained his Ph.D. under the supervision of Prof. Bernd Giese in 1990. Subsequently, he spent one and a half years as a postdoctoral fellow in the group of Prof. Mark Bednarski at the University of California at Berkeley, USA. In 1992 he joined the agrochemical research department of Sandoz Agro AG, Switzerland, which is today, after two mergers, part of Syngenta Crop Protection AG. Since 22 years he is specialized in fungicide discovery. He is the author of more than 130 publications and patents and inventor of Syngenta's fungicide mandipropamid (Revus?, Pergado?).

Jurgen Dinges is a senior principal research scientist in the pharmaceutical research department at Abbvie, USA. He studied chemistry at the Technical University of Darmstadt, Germany, where he obtained his Ph.D. degree in organic chemistry and chemical engineering under the supervision of Prof. Frieder W. Lichtenthaler in 1991. After being awarded a Feodor-Lynen scholarship from the Humboldt foundation, he spent 18 months as a postdoctoral fellow in the group of Prof. William G. Dauben at the University of California at Berkeley, USA. In 1993 he joined the Department for Biochemistry at Syntex, USA, which today is part of Hoffmann-La Roche Ltd., Switzerland. In 1995 he joined the pharmaceutical research department at Abbott Laboratories, USA, which became part of Abbvie in 2013. Since 19 years he is specialized in drug discovery. He is an author on 57 publications and patents and a co-inventor of more than 10 clinical drug development candidates.